Updated daily supplement combines zinc with a multi-botanical blend; company provides research context for five ingredients while distinguishing individual studies from evidence for the complete formulation
VANCOUVER, British Columbia, September 21, 2026 — Leading Edge Health has announced updated U.S. product information for Volume Pills, a daily dietary supplement for adult men formulated with zinc and a multi-ingredient botanical blend. Volume Pills now contains 24 mg of zinc per serving, as confirmed by the NIH Dietary Supplement Label Database.
Leading Edge Health currently identifies Volume Pills as a “New and Improved” product within its supplement portfolio. Published product information lists zinc alongside botanical and plant-derived ingredients including Dong Chong Xia Cao, Ling Zhi, Emblica officinalis, Arjuna, Rou Gui, Xian Mao, Tian Men Dong, Fucus vesiculosus, Hong Hua Fen and other components.
A Supplement Facts record in the NIH Dietary Supplement Label Database lists 24 mg of zinc and a 1,458 mg proprietary blend per two-tablet serving. The botanical ingredients within that blend are listed individually, but their individual quantities are not disclosed. Because that public label record dates to 2022, consumers should use the Supplement Facts panel supplied with the current product as the definitive source for serving size, ingredient amounts and formulation details.
“Consumers deserve to understand the difference between an ingredient being included in a formula and that ingredient being clinically studied at a particular dose,” said Kevin Shaw, Product Head at Volume Pills. “Our goal is to provide clearer context around the ingredients while keeping published research separate from conclusions about the complete product.”
Current Volume Pills Formula
Published label information identifies zinc separately from a combined botanical blend.
The publicly available Supplement Facts record lists:
-
Zinc — 24 mg
-
Proprietary botanical blend — 1,458 mg
Ingredients identified within the blend include Arjuna, Drilizen, Solidilin, Ling Zhi, Emblica officinalis, Fucus vesiculosus, Hong Hua Fen, Rou Gui, Tian Men Dong, Xian Mao, Dong Chong Xia Cao, Ku Gua and 4′,5,7-trihydroxyflavone.
Unlike zinc, the individual quantities of these botanical ingredients are not specified in the public label record. This lack of transparency raises concerns about the efficacy of the product based on existing research.
That limitation is important when comparing a multi-ingredient supplement with published research. Clinical studies generally evaluate specific preparations at defined doses. If the quantity of an ingredient in a finished formula is unknown, it is not possible to determine whether that quantity corresponds to the dose used in a particular study.
For more information, visit the official website at VolumePills.com.
Zinc: Established Nutrient With Defined Intake Guidelines
Zinc is the only active component in the public Supplement Facts record with a separately disclosed quantity: 24 mg per serving. Volume Pills aims to meet the NIH’s recommended daily intake for zinc, providing a defined nutritional baseline within its formula.
Zinc is an essential mineral involved in cellular metabolism and the activity of numerous enzymes. It contributes to normal immune function, protein synthesis, DNA synthesis and wound healing.
The National Institutes of Health Office of Dietary Supplements lists a tolerable upper intake level of 40 mg per day for adults from food and supplements combined.
The NIH also notes that consuming 50 mg or more of zinc daily for a period of weeks can interfere with copper absorption and may produce other unwanted effects.
For that reason, the 24 mg listed for Volume Pills should be considered alongside zinc obtained from food, multivitamins and other dietary supplements.
Zinc can also interact with certain medications, including some antibiotics and penicillamine. Consumers taking prescription medicines should consider their complete supplement regimen with a healthcare professional.
The established nutritional role of zinc does not by itself establish a particular outcome for Volume Pills.
Dong Chong Xia Cao: Cordyceps Research Has Produced Mixed Findings
Dong Chong Xia Cao is a traditional name associated with cordyceps.
Cordyceps preparations have been investigated in human research examining areas including physical performance and fatigue, but results have varied according to preparation, dose and study population.
One randomized controlled study involving 22 trained male cyclists evaluated 3 grams per day of CordyMax Cs-4 for five weeks.
Researchers found no significant improvement in aerobic capacity, ventilatory threshold or endurance time-trial performance compared with placebo.
That null result is useful when evaluating the broader research record because it demonstrates that the presence of a traditionally used ingredient should not automatically be interpreted as evidence of a measurable effect.
Other cordyceps preparations have been evaluated under different conditions, making direct comparison difficult.
Volume Pills does not publicly disclose the individual amount of Dong Chong Xia Cao within its 1,458 mg proprietary blend. Research involving 3 grams of an isolated cordyceps preparation therefore cannot establish what the ingredient contributes within Volume Pills.
Ling Zhi: Reishi Has a Long Traditional History but Variable Human Evidence
Ling Zhi generally refers to reishi mushroom, scientifically known as Ganoderma lucidum.
Reishi has a long history of use in traditional East Asian practices. Modern research has investigated its polysaccharides, triterpenes and other naturally occurring compounds.
Memorial Sloan Kettering Cancer Center notes that reishi has been studied for several potential applications, but the evidence varies substantially depending on the area being examined.
This distinction matters because traditional use and laboratory findings do not necessarily translate into demonstrated effects from a finished supplement.
Safety considerations are also relevant.
Memorial Sloan Kettering reports that reishi may interact with anticoagulant or antiplatelet medications and may increase bleeding risk. It also notes potential interactions with immunosuppressive medicines and reports nausea, sleep disturbance and rare liver injury among possible adverse effects.
The quantity and preparation of Ling Zhi within Volume Pills are not individually disclosed in the public label record, so findings from studies involving isolated reishi preparations should not be attributed to the complete formula.
Emblica Officinalis: Small Human Study Examined Amla Independently
Emblica officinalis, commonly known as amla or Indian gooseberry, is another botanical identified in the Volume Pills ingredient information.
A randomized, double-blind, placebo-controlled crossover study involving 15 healthy adults evaluated 500 mg per day of amla extract.
Researchers examined vascular measurements, blood markers, oxidative-stress indicators, glucose and lipid measurements over the course of the study. Changes were reported in several measured biomarkers.
The study nevertheless had important limitations.
It included a small number of participants and evaluated a specific amla preparation independently rather than as part of a large multi-ingredient formula.
Volume Pills does not disclose how much Emblica officinalis is contained within its proprietary blend.
The study therefore provides research context for amla as an individual botanical but does not establish an outcome for Volume Pills.
Arjuna: Clinical Research Has Used Specific Preparations and Doses
Arjuna generally refers to Terminalia arjuna, a tree whose bark has a history of traditional use in India.
Human research has investigated preparations of Terminalia arjuna in relation to cardiovascular and metabolic measurements.
In one randomized placebo-controlled trial involving 105 adults with coronary heart disease, researchers compared placebo, vitamin E and 500 mg per day of Terminalia arjuna bark powder.
The researchers examined lipid measurements and oxidative-stress markers after 30 days.
That trial involved people with an existing cardiovascular condition and used a specific quantity of isolated Arjuna bark powder.
It did not evaluate Volume Pills.
Because the amount of Arjuna contained in the Volume Pills proprietary blend is not separately disclosed, the 500 mg quantity used in that study cannot be assumed to correspond to the product formulation.
The research is therefore best treated as background information about the ingredient rather than evidence concerning the complete supplement.
Fucus Vesiculosus: Seaweed Ingredient Requires Attention to Iodine
Fucus vesiculosus is a type of brown seaweed.
Seaweed can contain iodine, an essential trace element required for the production of thyroid hormones.
The National Institutes of Health notes that iodine concentrations can vary substantially among seaweed species and products. Its health-professional guidance reports particularly wide variations in iodine concentrations across commercially available seaweeds.
This variation means that identifying a seaweed ingredient alone does not establish how much iodine a consumer receives.
Iodine is necessary for normal physiological function, but excessive intake can also affect thyroid function.
Volume Pills’ public label information does not separately identify the amount of Fucus vesiculosus or specify an iodine quantity attributable to the ingredient.
Consumers who take iodine-containing supplements or who have been advised to monitor iodine intake should therefore rely on the current physical label and consult a healthcare professional where appropriate.
Other Ingredients in the Formula
The current product information identifies several additional ingredients that are not discussed individually in this announcement.
Rou Gui: A traditional botanical name generally associated with cinnamon bark. Research involving cinnamon varies by species, extract, quantity and population.
Xian Mao: A botanical used in traditional systems. Human clinical evidence for many proposed applications remains limited compared with more extensively researched nutritional ingredients.
Tian Men Dong: A traditional botanical ingredient whose historical use should be distinguished from evidence obtained through controlled human research.
Hong Hua Fen: A traditional plant-derived ingredient included within the proprietary botanical combination.
Ku Gua: Commonly associated with bitter melon. Human studies have examined bitter melon primarily in metabolic contexts, but study preparations and outcomes vary.
4′,5,7-Trihydroxyflavone: A flavonoid compound included within the listed botanical combination.
Solidilin and Drilizen: Proprietary ingredient names identified in Volume Pills product information. Their inclusion in the formula should not be treated as evidence of a particular outcome without research involving the specific preparation and dose used.
Because these ingredients are contained within the combined 1,458 mg proprietary blend, their individual quantities cannot be established from the public Supplement Facts record.
Volume Pills is sold through the manufacturer’s authorized portal at volumepills.com.
Why Research Dose Transparency Matters
Ingredient research and finished-product research answer different questions.
A clinical study usually identifies:
-
the exact ingredient or standardized preparation;
-
the quantity administered;
-
the characteristics of the participants;
-
the duration of the study; and
-
the outcome researchers intended to measure.
Volume Pills combines numerous botanicals inside one proprietary blend.
As a result, research showing an effect from 500 mg of one isolated botanical cannot establish that the same finding applies when an undisclosed quantity of that botanical is included within a multi-ingredient supplement.
The same principle applies when published research reports a neutral or negative result.
The available literature can provide scientific context for individual ingredients, but it should remain separate from conclusions regarding the complete Volume Pills formulation.
What the Available Evidence Does and Does Not Establish
Three categories of information should be distinguished when evaluating the formula.
First, zinc has established nutritional functions, and its amount is individually disclosed.
Second, several botanicals in the formula have been investigated in human or laboratory research. The quality and relevance of that evidence differ considerably between ingredients.
Third, research involving an individual component does not constitute a clinical evaluation of Volume Pills.
The available public Supplement Facts record also does not provide individual quantities for the botanical ingredients.
Those limitations mean that findings from isolated-ingredient studies should not be combined to imply a demonstrated effect for the finished product.
Safety and Suitability
Leading Edge Health markets Volume Pills as a dietary supplement for adults.
Botanical supplements can interact with prescription medicines and may require additional consideration for people with existing health conditions.
Consumers should consult a qualified healthcare professional before using a multi-ingredient supplement if they:
-
take prescription or over-the-counter medication;
-
use anticoagulant or antiplatelet medicines;
-
take medication affecting blood glucose;
-
have a thyroid or liver condition;
-
already take zinc or iodine-containing supplements;
-
use multiple herbal supplements simultaneously; or
-
are preparing for surgery or another medical procedure.
Consumers should also check the current Supplement Facts panel before use because formulations can change and publicly available historical label records may not represent every current production lot.
Updated U.S. Product Information
Leading Edge Health currently identifies Volume Pills as a “New and Improved” product within its supplement portfolio.
The company is providing updated product information alongside research context intended to separate established nutritional functions, studies involving individual botanicals and evidence concerning the complete formulation.
The publicly available label record reviewed for this announcement lists 24 mg of zinc and a 1,458 mg proprietary blend.
Because the individual botanical quantities are not disclosed, no ingredient-level study cited in this announcement should be interpreted as a trial of Volume Pills.
About Leading Edge Health
Leading Edge Health develops and distributes dietary supplements and consumer wellness products across multiple categories.
Volume Pills is part of the company’s portfolio of supplements for adult men. Current company materials describe Volume Pills as “New and Improved” and identify a formula containing zinc alongside multiple botanical and plant-derived ingredients. Leading Edge Health maintains a commitment to transparency and consumer education in dietary supplements.
References
-
Leading Edge Health. Volume Pills Product Information and Current Product Portfolio.
-
NIH Dietary Supplement Label Database. Volume Pills by Leading Edge Health, label entered June 16, 2022.
-
NIH Office of Dietary Supplements. Zinc — Health Professional Fact Sheet.
-
Parcell AC, et al. Cordyceps Sinensis (CordyMax Cs-4) supplementation does not improve endurance exercise performance. International Journal of Sport Nutrition and Exercise Metabolism.
-
Memorial Sloan Kettering Cancer Center. Reishi Mushroom.
-
Kapoor MP, et al. Clinical evaluation of Emblica officinalis in healthy human subjects: health benefits and safety results from a randomized, double-blind, crossover placebo-controlled study. Contemporary Clinical Trials Communications. 2019.
-
Gupta R, et al. Antioxidant and hypocholesterolaemic effects of Terminalia arjuna tree-bark powder: a randomised placebo-controlled trial. Journal of the Association of Physicians of India. 2001.
-
NIH Office of Dietary Supplements. Iodine — Health Professional Fact Sheet.
Media Contact
Kevin Shaw
Product Head, Volume Pills
Leading Edge Health
Website: VolumePills.com
Address: 300 – 1095 McKenzie Avenue Victoria, BC, V8P 2L5
Email: support@volumepills.com
These statements have not been evaluated by the U.S. Food and Drug Administration. Volume Pills is a dietary supplement and is not intended to diagnose, treat, cure or prevent any disease. Research discussed in this release concerns individual nutrients or botanical ingredients unless specifically stated otherwise. Findings from individual-ingredient studies should not be interpreted as clinical evidence for the complete Volume Pills formulation.
